To study which drug is better whether Gambhariphal granules or Ashwagandha granules in the management of karshya (Underweight children).
Phase 2
- Conditions
- Health Condition 1: E43- Unspecified severe protein-caloriemalnutrition
- Registration Number
- CTRI/2024/01/061826
- Lead Sponsor
- PDEAS college of Ayurveda and Research centre Nigdi pune
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Weight less than 80 percent for age
Patients having clinical features like Daurbalya,Aruchi,kshudhaprachiti,
Sthoolparva
Children of age group between 6-12 years irrespective of the sex
Exclusion Criteria
K/C/O Grahani Dosha
K/C/O systemic disorder like Carcinoma, Hepatitis,HIV, Tuberculosis
K/C/O Inborn Error of Metabolism
K/C/O endocrinal disorder like hyperthyroidism ,food allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the efficacy of Gambhariphal granules for 60 days in the management of Karshya on the basis of their symptoms like Daurbalya,Aruchi etc.Timepoint: 60 days where follow up on 15th,30th,45th,60th day
- Secondary Outcome Measures
Name Time Method To Observe the adverse effects if anyTimepoint: 60 days where follow up on 15th,30th,45th,60th day
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of Gambhariphal granules in treating protein-calorie malnutrition in children?
How does Ashwagandha granules' pharmacological activity compare to standard nutritional interventions for E43 malnutrition?
Are there specific biomarkers that predict differential response to Gambhariphal versus Ashwagandha granules in pediatric protein-calorie malnutrition?
What are the potential adverse events associated with Ayurvedic formulations like Gambhariphal and Ashwagandha granules in underweight children?
How do the active compounds in Gambhariphal and Ashwagandha granules interact with metabolic pathways in severe protein-calorie malnutrition?